Novartis
-
{
- All
- News
- Videos
-
Novartis India Q1 Results: Profit At Rs 32 Crore; Revenue Up 19% To Rs 104 Crore
Novartis India Q1 net profit rose 16.7% to Rs 32.2 crore, while revenue increased 18.7% to Rs 104 crore. Ebitda jumped 29.2% year-on-year
-
Swiss Drug Major Novartis AG To Sell India Arm To ChrysCapital-Led Group
As part of the transaction, three acquirers, namely WaveRise Investments Limited, ChrysCapital Fund X and Two Infinity Partners, will collectively purchase the promoter stake.
-
Novartis, Roche Near US Drug Price Deal In Easing of Swiss Trade Tensions
Pfizer Inc., AstraZeneca Plc and other companies have struck deals with the Trump administration in recent months
-
Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based drugmaker's revenue.
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Is The Thrill Gone? MNC Pharma's Future In India
Several pharma MNCs are selling their brands to Indian companies, and downsizing their sales and marketing teams. Here's why.
-
Is The Thrill Gone? MNC Pharma's Future In India
Several pharma MNCs are selling their brands to Indian companies, and downsizing their sales and marketing teams. Here's why.
-
What Dr. Reddy's Stands To Gain From Buying Novartis' India Business
Novartis India's brands could complement Dr Reddy’s existing presence in those segments, according to Nomura.
-
What Dr. Reddy's Stands To Gain From Buying Novartis' India Business
Novartis India's brands could complement Dr Reddy’s existing presence in those segments, according to Nomura.
-
Dr. Reddy's Hits Life High On Reports Of Acquiring Novartis India
Novartis AG has commenced the strategic review that will include an assessment of its 70.68% shareholding in the India unit.
-
Is Novartis Planning To Sell Its India Unit?
Media reports suggest that drugmaker Dr. Reddy's Laboratories Ltd. is in the race to acquire the Novartis AG's stake in Novartis India.
-
Novartis Considering Sale Of Alcon Eye Care Division, Says Chairman
Alcon will take longer to turn around than expected, chief executive Joe Jimenez said in October, forecasting unit sales to be flat to slightly down in the current quarter.
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
-
GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand
Completion of the buyout by GSK of Novartis 36.5% stake in the joint venture is currently expected to occur during the summer of 2018.
-
Novartis India Q1 Results: Profit At Rs 32 Crore; Revenue Up 19% To Rs 104 Crore
Novartis India Q1 net profit rose 16.7% to Rs 32.2 crore, while revenue increased 18.7% to Rs 104 crore. Ebitda jumped 29.2% year-on-year
-
Swiss Drug Major Novartis AG To Sell India Arm To ChrysCapital-Led Group
As part of the transaction, three acquirers, namely WaveRise Investments Limited, ChrysCapital Fund X and Two Infinity Partners, will collectively purchase the promoter stake.
-
Novartis, Roche Near US Drug Price Deal In Easing of Swiss Trade Tensions
Pfizer Inc., AstraZeneca Plc and other companies have struck deals with the Trump administration in recent months
-
Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based drugmaker's revenue.
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs
The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.
-
Is The Thrill Gone? MNC Pharma's Future In India
Several pharma MNCs are selling their brands to Indian companies, and downsizing their sales and marketing teams. Here's why.
-
Is The Thrill Gone? MNC Pharma's Future In India
Several pharma MNCs are selling their brands to Indian companies, and downsizing their sales and marketing teams. Here's why.
-
What Dr. Reddy's Stands To Gain From Buying Novartis' India Business
Novartis India's brands could complement Dr Reddy’s existing presence in those segments, according to Nomura.
-
What Dr. Reddy's Stands To Gain From Buying Novartis' India Business
Novartis India's brands could complement Dr Reddy’s existing presence in those segments, according to Nomura.
-
Dr. Reddy's Hits Life High On Reports Of Acquiring Novartis India
Novartis AG has commenced the strategic review that will include an assessment of its 70.68% shareholding in the India unit.
-
Is Novartis Planning To Sell Its India Unit?
Media reports suggest that drugmaker Dr. Reddy's Laboratories Ltd. is in the race to acquire the Novartis AG's stake in Novartis India.
-
Novartis Considering Sale Of Alcon Eye Care Division, Says Chairman
Alcon will take longer to turn around than expected, chief executive Joe Jimenez said in October, forecasting unit sales to be flat to slightly down in the current quarter.
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
-
GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand
Completion of the buyout by GSK of Novartis 36.5% stake in the joint venture is currently expected to occur during the summer of 2018.
